Hypogonadism in testicular cancer patients is associated with risk factors of cardiovascular disease and the metabolic syndrome
(2017) In Andrology 5(4). p.711-717- Abstract
More than 95% of testicular cancer are cured but they are at increased long-term risk of cardiovascular disease. The risk of cardiovascular disease and treatment intensity was reported, but it is unknown whether this effect of cancer therapy is direct or indirect, mediated through androgen deficiency. Our aim was, therefore, to evaluate whether testicular cancer patients have increased the prevalence of risk factors of cardiovascular disease and if these risk factors are associated with hypogonadism and/or the cancer treatment given. In 92 testicular cancer patients (mean 9.2 years follow-up) and age-matched controls, blood samples were analysed for lipids, total testosterone, luteinizing hormone (LH), glucose and insulin. An estimate... (More)
More than 95% of testicular cancer are cured but they are at increased long-term risk of cardiovascular disease. The risk of cardiovascular disease and treatment intensity was reported, but it is unknown whether this effect of cancer therapy is direct or indirect, mediated through androgen deficiency. Our aim was, therefore, to evaluate whether testicular cancer patients have increased the prevalence of risk factors of cardiovascular disease and if these risk factors are associated with hypogonadism and/or the cancer treatment given. In 92 testicular cancer patients (mean 9.2 years follow-up) and age-matched controls, blood samples were analysed for lipids, total testosterone, luteinizing hormone (LH), glucose and insulin. An estimate of insulin resistance, HOMAir was calculated. Hypogonadism was defined as total testosterone < 10 nmol/L and/or LH > 10 IU/L and/or androgen replacement. In testicular cancer men with hypogonadism, compared with eugonadal patients, higher insulin (mean difference: 3.10 mIU/L; p = 0.002) and HOMAir (mean difference: 0.792; p = 0.007) were detected. Hypogonadism group presented with increased risk (OR = 4.4; p = 0.01) of metabolic syndrome. Most associations between the treatment given and the metabolic parameters became statistically non-significant after adjustment for hypogonadism. In conclusion, testicular cancer patients with signs of hypogonadism presented with significantly increased risk of metabolic syndrome and investigation of endocrine and metabolic parameters is warranted in these patients.
(Less)
- author
- Bogefors, C. ; Isaksson, S. ; BOBJER, JOHANNES LU ; Kitlinski, M. LU ; Leijonhufvud, I. LU ; Link, Katarina LU and Giwercman, A. LU
- organization
- publishing date
- 2017-07-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- hypogonadism, metabolic syndrome, risk, testicular cancer
- in
- Andrology
- volume
- 5
- issue
- 4
- pages
- 7 pages
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000406930900014
- pmid:28544654
- scopus:85024371510
- ISSN
- 2047-2919
- DOI
- 10.1111/andr.12354
- language
- English
- LU publication?
- yes
- id
- 32872fd3-4590-424b-ae9e-2582e8fd2b24
- date added to LUP
- 2017-08-04 11:16:46
- date last changed
- 2024-04-14 16:01:30
@article{32872fd3-4590-424b-ae9e-2582e8fd2b24,
abstract = {{<p>More than 95% of testicular cancer are cured but they are at increased long-term risk of cardiovascular disease. The risk of cardiovascular disease and treatment intensity was reported, but it is unknown whether this effect of cancer therapy is direct or indirect, mediated through androgen deficiency. Our aim was, therefore, to evaluate whether testicular cancer patients have increased the prevalence of risk factors of cardiovascular disease and if these risk factors are associated with hypogonadism and/or the cancer treatment given. In 92 testicular cancer patients (mean 9.2 years follow-up) and age-matched controls, blood samples were analysed for lipids, total testosterone, luteinizing hormone (LH), glucose and insulin. An estimate of insulin resistance, HOMAir was calculated. Hypogonadism was defined as total testosterone < 10 nmol/L and/or LH > 10 IU/L and/or androgen replacement. In testicular cancer men with hypogonadism, compared with eugonadal patients, higher insulin (mean difference: 3.10 mIU/L; p = 0.002) and HOMAir (mean difference: 0.792; p = 0.007) were detected. Hypogonadism group presented with increased risk (OR = 4.4; p = 0.01) of metabolic syndrome. Most associations between the treatment given and the metabolic parameters became statistically non-significant after adjustment for hypogonadism. In conclusion, testicular cancer patients with signs of hypogonadism presented with significantly increased risk of metabolic syndrome and investigation of endocrine and metabolic parameters is warranted in these patients.</p>}},
author = {{Bogefors, C. and Isaksson, S. and BOBJER, JOHANNES and Kitlinski, M. and Leijonhufvud, I. and Link, Katarina and Giwercman, A.}},
issn = {{2047-2919}},
keywords = {{hypogonadism; metabolic syndrome; risk; testicular cancer}},
language = {{eng}},
month = {{07}},
number = {{4}},
pages = {{711--717}},
publisher = {{Wiley-Blackwell}},
series = {{Andrology}},
title = {{Hypogonadism in testicular cancer patients is associated with risk factors of cardiovascular disease and the metabolic syndrome}},
url = {{http://dx.doi.org/10.1111/andr.12354}},
doi = {{10.1111/andr.12354}},
volume = {{5}},
year = {{2017}},
}